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Clinical liver function tests 
1. Introduction 
Liver failure is the major cause of mortality and morbidity after partial liver resection, and 
develops as a result of insufficient functional remnant liver (FRL) mass.1 Post-resectional liver 
function largely depends on the quantity and quality of the remnant liver, the latter being inversely 
proportional to underlying liver disease such as steatosis, cirrhosis, and cholestasis. Assessment of 
liver function is therefore crucial in the preoperative work-up of patients who require (extensive) 
liver resection.  
 CT volumetry is currently the standard method to determine whether a patient can safely 
undergo liver resection. When using CT volumetry, a liver resection can be safely performed when 
FRL volume is larger than 25-30% of total liver volume in case of normal liver parenchyma.2,3 In 
patients with underlying liver disease, a margin of 40% is taken into account.4 However, liver 
volume does not necessarily reflect liver function, especially in patients with a compromised 
liver.5,6 Therefore, it is important to reliably assess hepatic function before liver surgery in addition 
to CT volumetry.  
Several liver function tests have been developed in the last decade, including passive liver 
function tests (biochemical parameters and clinical grading systems), dynamic quantitative liver 
function tests (time-based uptake or metabolic capacity of infused compounds), molecular nuclear 
imaging techniques, and bioenergetic tests. This review will primarily focus on dynamic tests for 
the measurement of hepatic function before liver surgery. In addition, the application of 
quantitative liver function tests is discussed from the perspective of preoperative risk assessment in 
patients with diseased liver parenchyma. 
 
2. Definition of liver function and clinical implications 
The liver is responsible for a spectrum of functions including the uptake, metabolism, conjugation, 
and excretion of various endogenous and foreign substances, in which transporters play an 
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important role (Figure 1). The liver also provides an immunological function, as the 
reticuloendothelial capacity of the liver plays a role in phagocytosis, and clearance of micro-
organisms and endotoxins from the portal blood.7 The secretion of bile is an important end-point of 
liver function and the production of bile immediately ceases when perfusion of the liver is arrested. 
The complexity of liver function is best reflected by our inability to restore full liver function 
during liver failure, insofar as liver assist devices and bioartificial livers have not proven to fully 
substitute all the components of liver function yet.8,9 In addition, there is no liver function test 
available that measures all components of liver function. 
 Whereas the definition of liver function is comprehensive, a unanimous definition of 
posthepatectomy liver failure is lacking in literature.10 This makes comparison between study 
outcomes difficult. Recently, a definition of posthepatectomy liver failure has been proposed which 
allows objective comparisons in future studies.10 Nevertheless, liver surgery starts and ends with 
restricted information on the functionality of the organ with insufficient objective means to gauge 
whether the liver is failing postoperatively. Liver failure in addition depends on whether the 
preoperative remnant liver function has been preserved during the surgical procedure.  There are 
many variations in surgical techniques, and possibilities of technical errors that may lead to 
deterioration of remnant liver function.  Consequently, none of the available tests is completely 
accurate in predicting postoperative function of the remnant liver.11  
 
3. Passive liver function tests 
3.1. Bilirubin  
Plasma bilirubin concentration provides indirect information on the uptake, conjugation, and 
excretion function of the liver. Elevated plasma concentrations of bilirubin are specific markers for 
serious liver injury, and therefore liver function loss. After formation of unconjugated (‘indirect’) 
bilirubin, it is bound to albumin for transport to the liver. Bilirubin is taken up by hepatocytes, 
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where it is bound by a group of cytosolic proteins, mainly glutathione S-transferases (GST), to 
prevent efflux from the cell.12 Bilirubin is conjugated to glucuronic acid (‘direct bilirubin’) under 
the catalytic activity of UDP-glucuronosyltransferase 1-1 (UGT-1A), which converts conjugated 
bilirubin from a highly hydrophobic molecule to a relatively hydrophilic molecule.12 Conjugated 
bilirubin is then excreted into the bile across the canalicular membrane as bilirubin diglucuronide 
by the conjugate export pump multidrug resistance protein 2 (MRP2, ABCC2).13,14 
 The specific organic anion transporting polypeptide (OATP) transporter for bilirubin 
remains controversial.15 Bilirubin is transported into the cell more effectively by OATP1B1 than 
by OATP1B3, which was demonstrated in uptake studies using OATP1B1- or OATP1B3-
transfected X. laevis oocytes.16 Contrastingly, Cui et al14 reported that the transport of bilirubin into 
human embryonic kidney cells (HEK293) is facilitated by OATP1B1 but not OATP1B315, whereas 
Wang et al showed that a role for OATP1B1 in bilirubin transport is unlikely.17 However, recent 
pharmacogenetic studies have linked polymorphisms in the SLCO1B1 and SLCO1B3 genes, which 
encode the OATP1B1 and 1B3 isoforms, to elevated serum levels of unconjugated and conjugated 
bilirubin.18-20 Similarly, mice lacking the Sclo1a and Slco1b genes exhibit a >40-fold increase in 
total serum bilirubin levels (predominantly conjugated bilirubin), and a 2.5-fold increase in 
unconjugated bilirubin, while conjugated bilirubin in serum is undetectable in the parent strain.21 
Moreover, inactivation or disruption of Slco1b2 in mice leads to mild hyperbilrubinemia.22,23  
 Given the relevance of the OATP1B1 and 1B3 isoforms in the uptake of unconjugated and 
conjugated bilirubin, any liver pathology that affects OATP expression automatically alters 
bilirubin kinetics. For example, cytokines released by Kupffer cells during liver inflammation (e.g., 
during cholestasis, steatosis/steatohepatitis) and ischemia/reperfusion24 can influence the 
expression of different OATP isoforms independently25,26, and hence skew bilirubin-related test 
outcomes.  
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 Additionally, bilirubin levels may also be influenced by non-hepatic factors such as an 
increased production as results of e.g., hemolysis during sepsis.27 Hemoglobin and lactic acid 
dehydrogenase (LDH) are released during hemolysis, which result in an increase in indirect 
bilirubin and urobilinogen, a product of bilirubin reduction that becomes elevated in certain liver 
diseases such as hepatitis. Therefore, plasma bilirubin concentration is not a parameter of liver 
function per se in these instances. The plasma bilirubin concentration is often used in combination 
with other laboratory markers of hepatopathology (e.g., liver aminotransaminase levels, albumin 
levels), and/or clinical grading systems such as the Child-Pugh (see sections 4.1) and MELD 
(model for end-stage liver disease) scores. 
 
3.2. Albumin and coagulation factor synthesis  
Albumin and proteins involved in secondary hemostasis and fibrinolysis, including vitamin K-
dependent coagulation proteins (factors II, VII, IX, X, protein C, protein S, and protein Z), as well 
as factor V, XIII, fibrinogen, antithrombin, α2-plasmin inhibitor, and plasminogen, are exclusively 
synthesized by the liver, and their plasma concentrations are therefore used as indirect indicators of 
liver synthesis function. Albumin, clotting factors, and coagulation parameters such as the 
international normalized ratio (INR) are measured by routine clinical chemistry. In liver disease 
there is a decrease in the synthesis of albumin and coagulation factors, resulting in an increase in 
prothrombin time (PT) and INR. 
 
4. Clinical grading systems  
Clinical grading systems such as the Child-Pugh, and MELD scores combine several biochemical 
parameters with clinical symptoms of insufficient liver function. For liver resections, the Child-
Pugh score is deemed more relevant inasmuch as the MELD score is very narrow in patients 
undergoing liver resection. 
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4.1. Child-Pugh score 
The Child-Pugh score, a widely used clinical scoring system, includes total plasma bilirubin level, 
plasma albumin level, and PT together with the presence or absence of encephalopathy and ascites. 
The Child-Pugh scoring system is particularly useful in selecting patients with HCC and cirrhosis 
for resection or transplantation. In Western clinical practice, most class Child B and class Child C 
patients are candidates for transplantation, leaving class Child A patients eligible for resection. In 
these Child A patients, the Child-Pugh score has been shown to be quite variable and may be 
unreliable for predicting the outcome of liver resections.28-30  
 
5. Dynamic quantitative liver function tests  
Dynamic quantitative liver function tests measure the elimination of a substance in time. Since the 
substances used for these tests are cleared and/or metabolized almost exclusively by the liver, the 
dynamic quantitative liver function tests constitute a more accurate measure of the specific aspects 
of liver function. 
 
5.1. Indocyanine green (ICG) clearance test 
The ICG clearance test was initially devised for the measurement of blood flow, and later 
employed for the assessment of liver function by measuring functional hepatocyte mass. It is now 
the most widely used quantitative liver function test in the clinical setting.31 ICG is a 
tricarbocyanine dye that binds to albumin32,33, alpha-1lipoproteins28, and β-lipoproteins.32 It 
distributes uniformly in the blood within 2-3 minutes after intravenous injection of 25 mg or 50 mg 
ICG (dissolved in 5 mL or 10 mL sterile water, respectively). ICG is exclusively cleared by 
hepatocytes via OATP1B3 and sodium-taurocholate co-transporting polypeptide (NTCP)15, and 
excreted into the bile without biotransformation32,34,35 by the ATP-dependent export pump 
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multidrug-resistance-associated protein 2 (MRP 2).36 Under normal conditions, ICG has a high 
hepatic extraction rate, and its uptake is rate-limited by blood flow.15,33 Additionally, the clearance 
of ICG from the blood is similar to that of various endogenous and exogenous substances such as 
bilirubin, hormones, drugs, and toxins. The ICG clearance test therefore reflects several important 
functional parameters of the liver, including blood flow-dependent clearance and transporter 
capacity.15 
 Elimination of ICG from the blood is dependent on hepatic blood flow, cellular uptake, and 
biliary excretion.35,37 Following administration, the blood level falls exponentially for about 20 
minutes, by which time approximately 97% of the dye is excreted into the bile.34 ICG clearance is 
determined by serum sampling or pulse dye densitometry using an optical sensor placed on the 
finger.38-40 The results of ICG tests can be expressed in several ways, including the plasma 
disappearance rate (ICG-PDR), the ICG elimination rate constant (ICG-k), and the ICG-R15, 
which describes the percent of clearance of ICG at 15 minutes or, conversely, circulatory retention 
of ICG during the first 15 minutes following bolus injection.41 ICG-PDR is the most commonly 
used parameter, with normal ranges between 16-25%/min.32,37,42 
The ICG clearance test has been widely used in critically ill patients, and in patients with 
chronically reduced hepatic function.32,37 For example, it has been reported that the ICG-R15 value 
is a better indicator of liver function than the Child-Pugh classification in patients who had 
undergone cardiac surgery. In these patients a high ICG retention rate at 15 minutes correlated with 
a high rate of mortality.43 Furthermore, the ICG clearance test was found to be a better 
discriminating preoperative test for evaluating hepatic functional reserve in patients with HCC than 
the aminopyrine breath test, and the amino acid clearance test.44 Monitoring of ICG elimination is 
also indicated for the evaluation of liver function in organ donors and recipients in the liver 
transplantation setting. Several cut-off values for a safe resection have been described in the 
literature. The ICG-PDR is an important prognostic factor for postoperative recovery and survival, 
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and has to be higher than 5%/min.45 Another study reported a safety limit of ICG-R15 of 14% for a 
major hepatectomy.44  
However, under certain conditions ICG clearance test results may be misrepresentative of 
the underlying liver disease, as confirmed by several studies that found no significant correlations 
between ICG-15 clearance rates and liver histology as well as clinical outcome.46,47 Mortality has 
been noted in patients with normal ICG-15 values, and survival has been observed in patients with 
predicted poor outcome on the basis of preoperative ICG-15 values.46,48,49 Moreover, factors such 
as hepatic hemodynamics may influence test outcomes. Variations in hepatic blood flow caused by 
e.g., intrahepatic shunting or thrombosis will influence ICG clearance rate, rendering the test less 
predictive.47 Under pathophysiological circumstances, the transport capacity may be reduced due 
to downregulation of OATP transporters50 or by competitive inhibition by excessively present 
bilirubin.14 With respect to the former, cytokines such as TNF-α and IL-6, which are released by 
Kupffer cells in patients with e.g., steatosis and hepatitis, can affect the expression of OATP 
isoforms and NTCP, thereby affecting ICG uptake by the liver.15 Consequently, the ICG test may 
be of limited value during liver diseases in which the parenchyma is compromised, and is improper 
for cholestatic patients. Another aspect of the ICG clearance test is that it reflects global liver 
function but does not take into account regional variations that may occur in the liver, particularly 
under pathological conditions, thereby obscuring a possible functional disadvantage of the 
segments to be preserved. However, this applies to every clearance test that is performed without 
an imaging component. 
 
5.2. Galactose elimination capacity (GEC) test 
The galactose elimination test determines the metabolic capacity of the liver. Galactose is 
phosphorylated intracellularly to galactose-1-phosphate by galactokinase. Galactose-1-phosphate is 
then converted to glucose-1-phosphate by the action of four enzymes in the Leloir pathway.51,52 
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Galactose is administered intravenously, and the GEC is calculated from serial serum samples from 
20 to 50 min postinjection, making the test somewhat time-consuming. The GEC has shown 
prognostic significance in chronic liver disease53,54, such as fulminant hepatic failure55, primary 
biliary cirrhosis56-58, and chronic active hepatitis.54,57,59 Abnormal clearance has also been 
frequently observed in patients with metastatic liver neoplasms.57 A low GEC-value can predict 
postoperative complications and death, whereas a high GEC-value is associated with longer 
survival.54 As is the case with most liver function tests, alterations in environmental conditions or 
liver metabolism will affect test outcomes. Galactose is an essential component of membrane 
glycoproteins, and glycolipids. During liver regeneration, an increased membrane synthesis can 
lead to an augmented galactose demand.24 Furthermore, galactose can be converted into glucose, 
which is used as an energy source during anaerobic respiration, especially during fasting.24 As a 
result, altered galactose kinetics during e.g., liver regeneration and fasting24,60 may provide false 
positive results with respect to liver function. In addition, GEC only measures total liver function. 
 
6. Molecular nuclear imaging techniques 
6.1. 99mTc-galactosyl serum albumin (GSA) scintigraphy 
99mTc-diethylenetriamine-pentaacetic acid-galactosyl human serum albumin (99mTc-GSA) is an 
analogue ligand of asialoglycoprotein (ASGP) that binds to ASGP receptors (ASGP-R) on the 
hepatocyte cell membrane.61,62 The ASGP-R consists of 2 subunits, hepatic lectins 1 and 2, and is 
expressed only on the hepatocyte sinusoidal surface facing the space of Disse.61-66 ASGPs are 
taken up by the ASGP-R via receptor-mediated endocytosis. The liver is the only uptake site for 
99mTc-GSA, and it is therefore an ideal agent for receptor-targeted, functional liver scintigraphy. A 
significant decrease in ASGP-R expression has been observed in patients with chronic liver 
problems30, coinciding with the accumulation of ASGPs in the circulation.67,68 
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Planar 99mTc-GSA scintigraphy has proven valuable for the assessment of liver function in 
cirrhotic patients, and demonstrated a good relationship with conventional liver function tests such 
as antithrombin, total and direct bilirubin, PT, ICG clearance69, Child-Pugh classification, and 
histology (hepatic activity index (HAI) score).47,70 A discrepancy between the ICG clearance test 
and 99mTc-GSA scintigraphy has been described in 9-20% of the patients, in whom the histological 
severity of disease was better reflected by 99mTc-GSA scintigraphy.71,72 Since bilirubin does not 
bind to ASGP-R, 99mTc-GSA scintigraphy is not influenced by hyperbilirubinemia.73 Also, as there 
is practically no biliary excretion of 99mTc-GSA, the radiocompound is perfectly suited for SPECT. 
On the other hand, the test is not suitable for the evaluation of biliary obstruction as a possible 
cause of secondary hepatocellular failure, as can be seen in cholangiocarcinoma patients.  
In dynamic 99mTc-GSA scintigraphy, images are obtained after an intravenous bolus of 
99mTc-GSA using a gamma camera positioned over the heart, and liver region. The blood clearance 
and hepatic uptake are obtained by probing regions of interest (ROIs) in the heart and liver, 
respectively, for the accumulation of radiolabel in time. For the actual kinetics of 99mTc-GSA 
receptor binding, several complex kinetic models have been developed. Although many different 
parameters can be calculated from different kinetic models, these are often too complex and 
therefore not widely used in the context of liver surgery.74 The hepatic uptake ratio of 99mTc-GSA 
(LHL15) and the blood clearance ratio (HH15) are the most commonly used parameters in planar 
dynamic 99mTc-GSA scintigraphy (Figure 2). The HH15 is calculated by dividing the radioactivity 
of the heart ROI at 15 minutes after 99mTc-GSA injection by that at 3 minutes after injection. 
LHL15 is calculated by dividing the radioactivity of the liver ROI by the radioactivity of the liver 
plus heart ROIs at 15 minutes after injection.71,75,76 The modified receptor index (MRI), which 
represents a quantitative measurement of hepatic function, can subsequently be determined by 
dividing the LHL15 by the HH15, calculated from the radioactivity of the liver and heart.71 
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Multiple studies have addressed the use of preoperative planar dynamic 99mTc-GSA 
scintigraphy for predicting postoperative complications.61,72,77,78 The preoperative hepatic uptake 
ratio of 99mTc-GSA (LHL15) proved a reliable indicator for predicting postoperative complications 
in patients with HCC and chronic liver disease, showing significantly lower values in patients with 
major postoperative complications.47,78 Specific cut-off values for LHL15 (0.900 and 0.875)72,77,78 
have been used to select patients with a high risk for complications. However, these cut-off values 
were mostly not based on robust risk analysis but rather set arbitrarily. Postoperative liver failure 
was also observed in patients with a relatively normal liver function (LHL15 >0.875). This can be 
explained by the fact that LHL15 only measures preoperative total liver function, and not the 
function of the FRL per se. 
99mTc-GSA scintigraphy can be combined with CT to add anatomical detail to the liver 
function test. Static 99mTc-GSA single photon emission computed tomography (SPECT) has the 
ability to measure segmental liver function, and functional liver volume.79,80 The outline extraction 
method is a simple technique to calculate the functional liver volume using a specific cut-off value 
to automatically outline the liver.79 Typically, a cut-off value of 35-39% is employed for 
delineating the liver.79,81 Although static SPECT has the ability to visualize regional differences in 
liver function,  functional liver volume measured by the outline extraction method, does not take 
into account the regional functional differences within the delineated liver volume.74 As an 
alternative to static SPECT, dynamic SPECT has been employed to measure the uptake dynamics 
of 99mTc-GSA in a 3-dimensional manner using a rapidly rotating, multidetector gamma camera.  
99mTc-GSA SPECT provides the opportunity to specifically assess FRL function.80,82 
Preoperative functional volume measured by static 99mTc-GSA SPECT has proven more suitable 
for predicting remnant liver function than CT volumetry in a study group with predominantly 
cirrhotic patients.79,80 In cirrhotic patients, advanced fibrosis is accompanied by a reduction in 
functional hepatocytes. The superiority of static 99mTc-GSA SPECT over CT volumetry can, in this 
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respect, be explained by the fact that 99mTc-GSA SPECT measures the functional hepatocyte 
mass82, whereas CT volumetry cannot distinguish between functional and non-functional liver 
tissue. In addition, tumor-induced compression of surrounding liver tissue, bile ducts79, and/or 
blood vessels83 can impact regional liver function, while liver volume is sustained over a longer 
time period. However, the aforementioned outline extraction method for static SPECT images is 
based on the assumption that liver function is uniformly distributed in the tissue included within 
the cut-off value. Especially in tumor-bearing but also compromised livers, function can be 
distributed heterogeneously.5,74,84 Therefore, total functional liver volume as measured by static 
99mTc-GSA SPECT does not necessarily correlate with the intrinsic liver function. This potential 
shortcoming may be circumvented by using dynamic planar 99mTc-GSA SPECT76,82 in a 3-
dimensional manner (i.e., by using a rapidly rotating, multidetector gamma camera74,76,82) with 
which the intrinsic FRL function can be measured. In addition, dynamic planar 99mTc-GSA SPECT 
can be used to predict postoperative complications with a high level of accuracy.82,85   
 
6.2. 99mTc-mebrofenin hepatobiliary scintigraphy  
 
99mTc-mebrofenin (99mTc-N-(3-bromo-2,4,6-trimethyacetanilide) iminodiacetic acid) is an 
iminodiacetic acid (IDA) analogue that circulates in albumin-bound form.44,86,87 Dissociation of 
mebrofenin from albumin occurs in the space of Disse, after which mebrofenin is taken up by 
hepatocytes via human OATP1B1, and OATP1B3.15 Similar to ICG, 99mTc-mebrofenin undergoes 
biliary excretion without undergoing biotransformation, and is therefore an ideal tracer for the 
biliary tract as well.15,88 The canalicular transporter includes multidrug resistance protein-2.89 
Although 99mTc-mebrofenin is not metabolized, the transport mechanism resembles the transport of 
various endogenous, and exogenous substances such as bilirubin, hormones, drugs, and toxins. 
99mTc-mebrofenin hepatobiliary scintigraphy (HBS) therefore measures a physiologically 
representative function of the liver. 
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  99mTc-labeled IDA analogues were first used for the diagnosis of multiple biliary 
diseases.86,90,91 More recently, the application of 99mTc-labeled IDA agents have been proposed for 
the assessment of liver function.92 Measurement of hepatic uptake function by the clearance rate of 
the IDA analogue Iodida was first described by Ekman et al.93 The hepatic uptake of mebrofenin is 
calculated in a similar manner as that of Iodida. Due to the rapid biliary excretion of mebrofenin, 
99mTc-mebrofenin HBS is primarily used for dynamic rather than static assessment of liver 
function. After intravenous injection of 99mTc-mebrofenin, dynamic HBS is performed with a 
gamma camera74 as addressed in the previous section on 99mTc-GSA scintigraphy. To determine 
global liver function, the hepatic uptake of 99mTc mebrofenin is determined by assigning a ROI 
around the liver, the heart (serving as blood pool), and the total field of view, as is illustrated in 
Figure 3 (top row).  
Three different time-activity curves are generated based on these ROIs with which the 
uptake rate (%/min) can be calculated. Radioactivity values acquired between 150 and 350 seconds 
post-injection are used to ensure that the calculations are made during a phase of homogenous 
distribution of the agent in the blood pool, before biliary excretion takes place.94,95 FRL function 
can then be calculated by dividing the summed counts (150-350s post injection) within the 
delineated FRL by the total liver counts within the same time frame, and multiplying this factor 
with total liver 99mTc-mebrofenin uptake rate. Finally, total liver 99mTc-mebrofenin uptake rate 
(%/min/m2) can be calculated by dividing the time-activity curve(s) by the patient’s body surface 
area which therefore individualizes the assessment according to patient characteristics.94,95 
 A clinical study compared the ICG clearance test with 99mTc-mebrofenin HBS in patients 
undergoing liver resection, and showed a good correlation between the two tests.95 In a 
subsequent study, HBS was validated as a tool to measure total liver function as well as FRL 
function before liver surgery.94 The latter was validated by comparing preoperative FRL function 
with actual postoperative remnant liver function immediately after surgery. A strong positive 
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correlation (r=0.95) was found between FRL function determined preoperatively and the actually 
measured value 24 hours after resection. Also, 3 months after the resection, there was a strong 
positive correlation (r=0.81) between liver function assessed by 99mTc-mebrofenin HBS and the 
ICG clearance test. A slightly weaker relationship (r=0.61) was found between functional liver 
regeneration and liver volume increase after 3 months, which may account for some of the 
discrepancies between volumetric regeneration of the remnant liver and clinical (i.e., functional) 
outcome after liver resection.94 
 Two clinical studies further validated the utility of 99mTc-mebrofenin HBS in the 
preoperative prediction of postoperative liver failure. A study by Dinant et al87 encompassed 46 
patients with and without parenchymal disease. Preoperative measurement of FRL function by 
planar dynamic 99mTc-mebrofenin HBS proved more valuable than measurement of FRL volume 
by CT volumetry for risk assessment of postoperative liver failure and liver failure-related 
mortality.87 A safe resection could be performed in patients with an FRL uptake above 2.5 
%/min/m2 body surface area (BSA), with a 3% chance of developing postoperative liver failure 
and liver failure-related mortality. However, in patients with a FRL uptake below 2.5 %/min/m2 
BSA, the risk of postoperative liver failure increased to 56%. A study by de Graaf et al6 addressed 
a population of high-risk patients requiring major hepatic resections (≥3 liver segments), where 
accurate measurement of FRL function is critical in the assessment of potential resectability. For 
this population, ROC curve analysis yielded an almost similar FRL function cut-off of  
2.7 %/min/m2 BSA. We now use 2.7 %/min/m2 BSA as the advised cut-off for FRL function. 
Owing to technical advances, new rotating gamma cameras have been developed that 
enable fast 99mTc-mebrofenin SPECT, thereby accounting for the rapid hepatic uptake and biliary 
excretion kinetics of mebrofenin. Dual-head gamma cameras now enable simultaneous data 
acquisition in the anterior and posterior projections, from which a geometric mean activity can be 
calculated, thereby reducing the attenuation bias. Additionally, these gamma cameras can be used 
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in conjunction with CT scanners to combine the functional data from 99mTc-mebrofenin SPECT 
with the anatomic information from the CT scan, enabling 3-dimensional measurement of 
segmental liver function and liver functional volume (Figure 3, bottom row). The FRL can be 
outlined manually on the low-dose CT scan and linked to the SPECT images. The delineated FRL 
on contrast-enhanced CT scans can subsequently be used as a constant reference. A recent study, in 
which FRL function was assessed by 99mTc-mebrofenin SPECT with low-dose CT, demonstrated 
that the combination of SPECT with the dynamic uptake data from planar HBS (geometric mean 
data) allowed complete and accurate prediction of postoperative remnant liver function5, whereby 
the SPECT and CT image overlays provided valuable visual information on liver function 
distribution. 
The timing of the SPECT is a challenge when a dynamic tracer such as 99mTc-mebrofenin is 
used, which is first taken up by the liver, and subsequently excreted in the bile. The SPECT 
acquisition is therefore centered around the peak of the hepatic time-activity curve, since the 
amount of radioactivity within the liver is relatively stable during this phase. In patients with fast 
hepatic uptake, biliary excretion is already visible during the SPECT phase. Accumulation of 
radioactivity in the small bile ducts results in voxels with relatively high counts, disturbing 
calculation of total and regional liver function, and volume. Consequently, the activity within the 
extrahepatic bile ducts must be masked out, and the intrahepatic bile ducts must be replaced by the 
average counts of the normal surrounding liver tissue. The outline extraction method can 
subsequently be used to automatically outline the liver, and calculate total functional liver volume.  
Furthermore, ROIs can be drawn around parts of the liver to calculate regional differences 
in 99mTc-mebrofenin uptake rate. Segmental liver function, such as that of the FRL, can be 
measured by dividing the counts within the delineated segment by the total counts within the entire 
liver. For calculation of the FRL function, this count ratio is multiplied by total liver 99mTc-
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mebrofenin uptake as measured by dynamic HBS. The regional uptake of 99mTc-mebrofenin can be 
assessed with small intra- and interobserver variation.87,94 
Because 99mTc-mebrofenin HBS has the ability to selectively measure FRL function, it is 
one of the few liver function tests that can be used to measure the increase in FRL function after 
PVE. A recent study showed that functional increase of the FRL measured by 99mTc-mebrofenin 
HBS exceeds the volumetric increase of the FRL, suggesting that the waiting time until resection 
may be shorter than indicated by volumetric data.96 
Liver uptake of IDA agents can be affected by high plasma levels of bilirubin because of 
the competitive affinity of bilirubin for the respective transporters. Of all IDA analogues, however, 
99mTc-mebrofenin shows the highest hepatic uptake, minimal urinary excretion, and a strong 
resistance against displacement by high plasma bilirubin concentration.97 Therefore, 99mTc-
mebrofenin is considered the most suitable IDA analogue for hepatic, and biliary diagnostic 
procedures. In addition, 99mTc-mebrofenin uptake can be hindered by hypoalbuminemia, as 
albumin is the main plasma carrier of mebrofenin. Nevertheless, hypoalbuminemia and 
hyperbilirubinemia can be a sign of impaired liver function during liver disease, and therefore a 
decreased uptake of 99mTc-mebrofenin in patients with hypoalbuminemia can still provide an 
accurate reflection of liver function under these circumstances. 
 
Discussion 
Accurate measurement of liver function before liver resection is crucial in the assessment of 
hepatic functional reserve and resectability, especially in patients who require major resection and 
patients with underlying parenchymal disease. For liver surgery, CT volumetry is currently the 
gold standard method to decide on resectability. Several quantitative liver function tests can 
complement CT volumetry, and may even replace CT volumetry in the future. 
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In patients with liver-specific diseases, accurate assessment of liver function is critical for 
the selection of treatment options. Liver steatosis and steatohepatitis, for example, are associated 
with an increased risk of liver failure after partial liver resection, especially after neo-adjuvant 
chemotherapy, or in living donor liver transplantation.98 When CT volumetry is used as a 
prognostic tool for surgical outcome, a functional overestimation can be made in patients with 
steatosis. The accumulation of triacylglycerols in hepatocytes leads to hepatocyte enlargement in 
combination with steatosis-induced perfusion defects; i.e., phenomena that distort the actual liver 
function when deduced from CT scans. ICG clearance and 99mTc-mebrofenin HBS therefore 
possess the potential to assess hepatic function in steatotic livers because of the combination of 
impaired parenchymal perfusion, and liver dysfunction.99  
The same principles apply to cirrhotic livers, where fibrosis is accompanied by a reduction 
in functional hepatocytes that concurs with the formation of fibrous tissue septa that separate 
hepatocyte nodules, leading to altered resistance to hepatic blood flow, and portal 
hypertension.100,101 The most commonly used liver function tests in cirrhotic patients include 
hyaluronic acid uptake, the Child-Pugh classification, 99mTc-GSA scintigraphy, and the ICG test, 
albeit any liver function test is capable of detecting a reduced number of functional hepatocytes in 
combination with impaired hepatic blood flow. In any case, liver function tests provide more 
accurate information on the functional status of the liver than CT volumetry. 
Prolonged cholestasis produces hepatocellular injury, and fibrosis. The uptake of 99mTc-
mebrofenin and ICG is impaired under these conditions due to competitive uptake of bilirubin and 
ICG/mebrofenin by the same cellular transporter systems. Although this impaired uptake is 
indicative of the uptake function of the liver at that specific time, it does not reflect the function of 
the liver after surgery once the biliairy obstruction has been resolved. Preoperative assessment of 
liver function using the ICG clearance test or 99mTc-mebrofenin HBS therefore requires complete 
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biliary drainage of at least the FRL in patients with concomitant obstruction of (part of) the biliary 
tree, as seen in hilar cholangiocarcinomas.  
The major disadvantage of most quantitative liver function tests such as the ICG clearance 
test and the GEC is the fact that they only measure global liver function, and not specifically the 
function of the FRL. Both 99mTc-GSA scintigraphy and 99mTc-mebrofenin HBS have the unique 
ability to measure FRL function non-invasively. These tests are therefore also suitable for 
assessing the increase in FRL function after PVE. In addition, they allow for the simultaneous 
acquisition of morphological (visual), and physiological (functional) information of the liver, 
especially when SPECT-CT cameras are used. It has been demonstrated in patients that the 
functional capacity may vary within the liver or even the FRL. With molecular imaging techniques, 
such regional differences in hepatic function can be detected. In addition, when 
radiopharmaceutical agents are used that are excreted into the bile, two dynamic phases can be 
examined, i.e., hepatic uptake of the agent and secretion into the biliary system. 
Both preoperative 99mTc-GSA and 99mTc-mebrofenin scintigraphy are validated and 
accurate methods for preoperative assessment of liver function and prediction of postoperative 
complications.72,87,95 Both tests are especially suitable for evaluation of liver function in patients 
with parenchymal liver disease. Unfortunately, the clinical implementation of 99mTc-GSA 
scintigraphy has been restricted as to date it has not been approved in Europe and the US, but only 
in Japan. 
 In the final analysis, the most suitable liver function test for clinical use is yet to be 
determined. However, recent studies have provided useful insights into the proper approach 
towards assessing preoperative liver function. De Graaf et al24 compared several quantitative liver 
function tests in a standardized rat model of liver regeneration, including liver volume (CT 
volumetry), 99mTc-GSA scintigraphy, 99mTc-mebrofenin HBS, the ICG clearance test, and the GEC 
test. It was clearly demonstrated that volumetric assessment of the liver should in any case be 
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complemented by liver function-specific tests. Due to the functional complexity of the liver, and 
because each test reflects a different component of liver function, one single liver function test 
cannot measure liver function comprehensively.102,103 It is therefore recommended to employ a 
liver function test that (1) can be combined with imaging (e.g., SPECT) to provide regional 
functional information, (2) measures a maximum number of components of liver function, and (3) 
is not restricted in its clinical implementation by regulatory agencies. These selection criteria 
automatically yield 99mTc-mebrofenin HBS as the most suitable liver function tests, given that this 
test (1) can be combined with SPECT, (2) measures the uptake (by two transporters) and excretory 
function of the liver, and (3) does not face regulatory restrictions such as e.g., 99mTc-GSA 
scintigraphy.  
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Figure 1. Schematic overview of two prominent features of liver function, basolateral and canalicular transport of 
compounds and protein synthesis, that are pertinent to this review. The anatomical features are identified and the 
arrows indicate the direction of transport. Hepatic transporters located at the basolateral side of hepatocytes (yellow 
structures) are responsible for the transport of compounds from the circulation into the cell (sodium-taurocholate co-
transporting polypeptide (NTCP) and the organic cation transporter (OCT) family, comprising the OCT1, OCT2, and 
OCT3 isoforms), out of the cell (two isoforms of the ATP-binding cassette (ABC) family: multidrug resistance-
associated protein (MRP)3 and MRP4), or bidirectionally (the organic anion transporting polypeptide (OATP) family, 
comprising the OATP1A2, OATP1B1, and OATP1B3 isoforms, and the organic transporter (OAT) family, comprising 
the OAT2 and OAT3 isoforms). The asialoglycoprotein receptor (ASGP-R) removes asialoglycoproteins from the 
circulation. Intracellularly transported compounds may undergo biotransformation (e.g., glucoronidation) or be 
metabolized (these liver function aspects are not shown), after which they may be transported back into the circulation 
or excreted into bile. All canalicular transporters (red structures) are unidirectional and include several members of the 
ABC family (MRP2, ATP-binding cassette sub-family B member (ABCG) 1 (also called multidrug resistance 
(MDR)1), MDR3 P-glycoprotein, and ATP-binding cassette sub-family G members (ABCG) 2, 5, and 8), the bile salt 
export pump (BSEP), and probable phospholipid-transporting ATPase IC (ATP8B1). The protein synthesis function is 
indicated by the DNA helix → protein crystal structure.  
 
Figure 2. Planar 99mTc-GSA scintigraphy. The hepatic uptake ratio (LHL15) and blood disappearance ratio (HH15) is 
calculated from the 99mTc-GSA time-activity curves from the heart (grey) and the liver (black) (left panel). The HH15 
is calculated by dividing the radioactivity of the heart ROI at 15 minutes after 99mTc-GSA injection by that at 3 minutes 
after injection. LHL15 is calculated by dividing the radioactivity of the liver ROI by the radioactivity of the liver plus 
heart ROIs at 15 minutes after injection.75The subscript values designate time, the capitalized letters indicate the organ 
according to the legend. The blood disappearance constant (KL) is calculated from the liver uptake curve using the 
disappearance halftime (T1/2) (right panel). Images adapted from [74]. 
 
Figure 3. 99mTc-mebrofenin hepatobiliary scintigraphy (HBS, top row) and 99mTc-mebrofenin SPECT (bottom row). 
The upper left panel shows superimposed images of dynamic planar HBS scans from 150-350 sec after intravenous 
injection of 99mTc-mebrofenin, which ensures that hepatic uptake calculations are performed during a phase of 
homogenous distribution of 99mTc-mebrofenin. A region of interest is drawn around the entire liver (red line), the 
mediastinum (blood pool, yellow line), the total field of view ( not shown) and the future remnant liver (FRL, green 
line). The respective, color-coded time-activity curves are depicted in the upper right panel. The time-activity curves of 
the liver (segments) are typically corrected for background, i.e., the blood pool time-activity curve, by subtraction. The 
uptake of 99mTc-mebrofenin (D) by the liver is calculated as an increase in blood pool-corrected 99mTc-mebrofenin 
uptake (y) over a predefined time interval (x), usually 200 seconds. 
The bottom left and right panels depict an example of 99mTc-mebrofenin SPECT with a matching CT scan. An 
inhomogeneous distribution of 99mTc-mebrofenin is seen in liver segments 7 and 8 (arrows) due to regional cholestasis 
in a patient with hilar cholangiocarcinoma. The matching CT scan shows dilated bile ducts (arrowheads) in the same 
liver segments. 
 



